Stephen R Kraus
Overview
Explore the profile of Stephen R Kraus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kraus S, Li J, Kristy R, Lockefeer A, Yang H, Zhou M, et al.
J Int Med Res
. 2022 May;
50(5):3000605221098176.
PMID: 35588263
Objective: To understand factors guiding overactive bladder (OAB) therapy selection and experience with combination therapy (antimuscarinics and beta-3 agonists). Methods: Cross-sectional surveys of OAB patients and OAB-treating physicians in the...
2.
Ginsberg D, Boone T, Cameron A, Gousse A, Kaufman M, Keays E, et al.
J Urol
. 2021 Sep;
206(5):1106-1113.
PMID: 34495688
Purpose: The clinician treating patients with neurogenic lower urinary tract dysfunction (NLUTD) needs to balance a variety of factors when making treatment decisions. In addition to the patient's urologic symptoms...
3.
The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation
Ginsberg D, Boone T, Cameron A, Gousse A, Kaufman M, Keays E, et al.
J Urol
. 2021 Sep;
206(5):1097-1105.
PMID: 34495687
Purpose: The clinician treating patients with neurogenic lower urinary tract dysfunction (NLUTD) needs to balance a variety of factors when making treatment decisions. In addition to the patient's urologic symptoms...
4.
Kraus S, Shiozawa A, Szabo S, Qian C, Rogula B, Hairston J
Neurourol Urodyn
. 2020 Aug;
39(8):2206-2222.
PMID: 32827230
Introduction: Treatment patterns and costs were characterized among patients with overactive bladder (OAB) receiving later-line target therapies (combination mirabegron/antimuscarinic, sacral nerve stimulation [SNS], percutaneous tibial nerve stimulation [PTNS], or onabotulinumtoxinA)....
5.
Johnson 2nd T, Burgio K, Kraus S
JAMA Intern Med
. 2020 May;
180(7):1025-1026.
PMID: 32391859
No abstract available.
6.
Burgio K, Kraus S, Johnson 2nd T, Markland A, Vaughan C, Li P, et al.
JAMA Intern Med
. 2020 Jan;
180(3):411-419.
PMID: 31930360
Importance: First-line behavioral and drug therapies for overactive bladder (OAB) symptoms in men are effective but not usually curative. Objective: To determine whether combining behavioral and drug therapies improves outcomes...
7.
Warsi Q, Huang A, Hess R, Arya L, Richter H, Bradley C, et al.
Obstet Gynecol
. 2018 Jan;
131(2):204-211.
PMID: 29324595
Objective: To evaluate the association between pharmacologic therapy for urgency urinary incontinence (UUI) and sleep quality. Methods: We conducted a planned secondary data analysis of sleep outcomes in a previously...
8.
Winkelman W, Warsi A, Huang A, Schembri M, Rogers R, Richter H, et al.
Female Pelvic Med Reconstr Surg
. 2018 Jan;
24(2):76-81.
PMID: 29300259
Objective: The objective of this study was to examine the strength and direction of the association between urinary symptoms and both poor quality sleep and daytime sleepiness among women with...
9.
10.
Kobashi K, Albo M, Dmochowski R, Ginsberg D, Goldman H, Gomelsky A, et al.
J Urol
. 2017 Jun;
198(4):875-883.
PMID: 28625508
Purpose: Stress urinary incontinence is a common problem experienced by many women that can have a significant negative impact on the quality of life of those who suffer from the...